A breakthrough in the field of targeted therapies
Valvian is a Portuguese biotechnology company dedicated to the development of innovative immunotherapies and targeted therapies for the treatment of cancer and age-related diseases.
Founded in 2024, Valvian combines excellent science with an integrated model of research, development and production of biological medicines, positioning itself as a new pillar of biotechnology in Portugal.
The company is a pioneer in glycobiology applied to medicine, exploring the role of glycans as new therapeutic targets. It uses proprietary artificial intelligence to identify new molecular targets, accelerate the discovery of new generation monoclonal antibodies and optimize the design of cell therapies and complex biologics.
Valvian develops monoclonal antibodies, advanced cell therapies (CAR-T and CAR-DC) and precision medicine programs, with the aim of creating more effective and personalized solutions for patients with solid tumors.
With a strong translational orientation and collaborations with academic centers and international partners, Valvian seeks to transform science into therapies with global impact.
